Table 2.
Variables | Placebo (n = 24) | Standard Deviation | Botulinum Toxin (n = 24) | Standard Deviation | p Value * | |
---|---|---|---|---|---|---|
QOL | 4 weeks (range) | 30.5 (15–42)) | 7.35 | 36 (16–48) | 0.06 | 9.52 |
6 weeks (range) | 32 (14–42) | 9.22 | 36 (11–48) | 0.04 | 9.55 | |
8 weeks (range) | 32 (14–42) | 8.69 | 36 (11–49) | 0.08 | 9.88 | |
VAS | 4 weeks (range) | 6 (1–10) | 2.30 | 3 (0–8) | 0.01 | 2.74 |
6 weeks (range) | 4 (1–10) | 2.63 | 4 (0–10) | 0.09 | 2.82 | |
8 weeks (range) | 4 (1–10) | 2.61 | 3 (0–8) | 0.09 | 2.73 | |
ESS | 4 weeks (range) | 8 (1–23) | 7.12 | 9 (1–21) | 0.73 | 6.36 |
6 weeks (range) | 9 (1–22) | 6.64 | 10 (1–22) | 0.46 | 6.29 | |
8 weeks (range) | 9 (1–33) | 7.97 | 10 (1–22) | 0.22 | 6.48 |
VAS—Visual Analog Scale, QOL—Johns Hopkins Quality of Life questionnaire, ESS—Epworth Sleepiness Scale. * Wilcoxon signed rank test.